Skip to main content
TipRanks
Go Ultimate75% OFF

Bruce Peacock Insider Profile

4 Followers

Bruce Peacock, Director at Ocular Therapeutix, holds 0.00 shares in Ocular Therapeutix (Ticker: OCUL), holds 8.89K shares in Windtree Therapeutics (Ticker: WINT), holds 0.00 shares in Dicerna Pharma (Ticker: DRNA).

Bruce Peacock's Trading History

OCUL
Ocular Therapeutix
Dec 07, 2020DirectorUninformative Buy127.18K$0.00
WINT
Windtree Therapeutics
May 27, 2020DirectorInformative Buy25.38K$106.63
ISEE
IVERIC bio
Sep 04, 2014―Uninformative Sell233.63K$0.00
OPTT
Ocean Power Technologies
―Director―$0.00
NGSX
Neurogesx
―――$0.00
LGND
Ligand Pharma
―Director―$6.12M
AGTC
Applied Genetic Technologies
―――$0.00
DRNA
Dicerna Pharma
―――$0.00

You May Also Like

Bruce Peacock insider profile FAQ

What is the percentage of profitable transactions made by Bruce Peacock?
The percentage of profitable transactions made by Bruce Peacock is 80%.
What is the average return per transaction made by Bruce Peacock?
The average return per transaction made by Bruce Peacock is 18.80%.
What stocks does Bruce Peacock hold?
Bruce Peacock holds: OCUL, WINT, DRNA, AGTC, ISEE, LGND, NGSX, OPTT stocks.
What was Bruce Peacock’s latest transaction?
Bruce Peacock’s latest transaction was an Uninformative Buy of $127.18K.
What was Bruce Peacock's most profitable transaction?
Bruce Peacock’s most profitable transaction was an Informative Sell of OCUL stock on December 7, 2020. The return on the trade was 66.70%.
What is Bruce Peacock's role in Ocular Therapeutix?
Bruce Peacock's role in Ocular Therapeutix is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.